Aligos Therapeutics, Inc. (ALGS) – What Are Researchers Thinking About This Stock?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $38.50.

ALGS has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating on shares of Aligos Therapeutics in a research note on Monday, August 10th. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Finally, Jefferies Financial Group upgraded Aligos Therapeutics to a “strong-buy” rating in a research note on Friday, September 25th.

Aligos Therapeutics Stock Performance

Shares of Aligos Therapeutics stock opened at $4.86 on Monday. The company has a market cap of $30.33 million, a PE ratio of -0.67 and a beta of 2.36. The company has a 50 day moving average of $5.96 and a 200-day moving average of $5.95. Aligos Therapeutics has a 1-year low of $3.98 and a 1-year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.95. The firm had revenue of $27.78 million for the quarter, compared to the consensus estimate of $24.68 million. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%. Research analysts forecast that Aligos Therapeutics will post -6.81 earnings per share for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ALGS. Bank of America Corp DE raised its position in Aligos Therapeutics by 1,652.8% in the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after purchasing an additional 216,646 shares during the last quarter. SummitTX Capital L.P. boosted its stake in shares of Aligos Therapeutics by 6.7% during the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock valued at $1,106,000 after purchasing an additional 9,375 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Aligos Therapeutics by 17.6% during the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after purchasing an additional 15,006 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its stake in shares of Aligos Therapeutics by 900.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares in the last quarter. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic liver diseases and other viral infections. The company’s research programs are designed to address significant unmet needs in conditions including chronic hepatitis B virus (HBV) infection, hepatitis D virus (HDV) infection and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis.

Aligos’ pipeline includes investigational therapies intended to target different stages of disease biology.